Hypertension is a key focus of our work in cardiovascular medicine.
The incidence of hypertension is estimated at 30% in the UK and Ireland. Raised blood pressure is a major risk factor for coronary heart disease and ischemic as well as haemorrhagic stroke, with blood pressure levels positively and continuously related to risk. Over the last two decades we have carefully selected and trained both GP and Hospital sites in Ireland and the UK to run clinical trials in hypertension, and to use 24 hour Ambulatory Blood Pressure Measurement (ABPM) in clinical trials.
24 hour ABPM is increasingly used in clinical research to assess anti-hypertensive drug efficacy and to evaluate the off-target blood pressure effects of non cardiovascular drugs.
ABPM provides better data on blood pressure changes during normal activities, including daytime and nighttime changes in blood pressure. ABPM is also free from ‘white coat hypertension’ effects and other short-term changes in blood pressure that can obscure blood pressure changes in clinical trials. ABPM is therefore considered a better standard than casual of ‘office’ readings in the medical and scientific community.
Java’s expertise in hypertension has developed through our close working relationship with the world renowned hypertension specialist, Professor Eoin O’Brien. Working with Professor O’Brien, our focus has been on the application of 24 hour ABPM in the clinical trial setting.
The team here at Java Clinical Research have considerable practical experience with the implementation, collection and analysis of ABPM data in clinical trials, which can be tailored to suit your specific needs.